June 11, 2019 I We just released a new report describing and analyzing the field of bispecific antibodies used to redirect T-cells or natural killer (NK) cells to tumor cells. Since our first report about this subject three years ago, this specific field of biopharmaceutical research has grown enormously as evidenced by nearly twice as many product candidates in clinical development than three years ago. Furthermore, nearly all major pharmaceutical companies are active in this field, partly with in-house technologies used for generation of bispecific T-cell and NK cell engagers, but mostly in R&D collaboration and licensing agreements with technology companies. A major side effect of this strong deal making activity is the rather good funding situation of technology providing companies.

The good funding situation is one of the opportunities which is offering this field. Another is the perspective of improvement of first generation bispecific antibody technology. Having a long half-life is a must for novel bispecifics: established first generation bispecific T-cell engaging antibody technologies have evolved to half-life extended (HLE) versions. Safety and efficacy are now the dominant area of improvement, including the prodrug concept, localized expression of bispecifics, recruitment of specific subsets of T-cells or natural killer cells as a safer and effective option. The most recent deals have focused such next generation constructs.

A still largely untapped area of bispecific T-cell or NK cell engagers is that of targeting intracellular targets via the peptide/MHC complex. Although the currently most advanced bispecific T-cell engager is a gp100-targeted molecule, only very few companies have focused on this specialty technology involving the T-cell receptor (TCR) as targeting domain.

Our new report entitled T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysisbrings you up-to-date information about major pharmaceutical and technology companies active in the field, state of the art and emerging next generation technologies, subject and economic terms of partnering deals and a pipeline analysis of product candidates including clinical experiences.

Analysis is based on the profiles of 56 Big Pharma and technology companies covering company background/history, financial situation, technology overview, partnering activities and pipeline overviw. 38 different technologies to create bispecific T-cell and NK cell engaging antibodies are profiled in depth. Pipeline analysis is based on the profiles of 90 drug candidates in development. Sources of information are 237 scientific references. Non-scientific sources of information, such as press releases, annual reports and presentations, are disclosed within the text with an embedded hyperlink leading to the online source of information.

Sample pages and product description with Table of Contents, List of Tables and Related Companies can be found online at https://staging.lamerie.com/report/t-cell-nk-cell-engaging-bispecific-antibodies-2019-a-business-stakeholder-technology-and-pipeline-analysis/

SOURCE: La Merie Publishing